Published in PLoS Pathog on August 30, 2012
Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog (2014) 2.13
Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio (2013) 1.61
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog (2013) 1.09
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc Natl Acad Sci U S A (2013) 1.00
Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol (2014) 0.99
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Humanized mice for the study of infectious diseases. Curr Opin Immunol (2013) 0.92
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology (2014) 0.89
Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol (2015) 0.88
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol (2014) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. PLoS One (2013) 0.81
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl (2016) 0.80
In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design. Hepat Mon (2014) 0.80
Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses (2016) 0.80
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One (2014) 0.80
Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge. J Virol (2015) 0.78
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U S A (2016) 0.77
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology (2017) 0.76
Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl (2016) 0.76
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76
Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG. J Virol (2016) 0.76
Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. J Immunol (2016) 0.76
Nanopore-Based Target Sequence Detection. PLoS One (2016) 0.75
Optimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes. J Immunol Methods (2013) 0.75
Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology (2016) 0.75
Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. J Virol (2016) 0.75
Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Sci Rep (2016) 0.75
Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol (2016) 0.75
Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathog (2017) 0.75
Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol (2017) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
The global burden of hepatitis C. Liver Int (2009) 8.89
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis (2000) 6.05
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol (2008) 2.33
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol (2001) 2.19
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl (2006) 2.12
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem (2006) 2.02
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med (1997) 1.92
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Hepatitis C virus entry. J Biol Chem (2007) 1.91
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology (2005) 1.82
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology (1999) 1.76
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology (1999) 1.38
Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet (1976) 1.35
Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med (1998) 1.29
Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis (1996) 1.28
Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol (2007) 1.27
The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl (2003) 1.26
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl (2009) 1.10
Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology (2012) 1.06
Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation (2004) 1.02
Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation (2002) 1.00
Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl (2006) 0.98
Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet (1988) 0.87
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology (2012) 3.94
The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell (2012) 3.91
Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry (2005) 3.85
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A (2004) 3.74
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A (2008) 3.68
A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature (2013) 3.55
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis E virus. Rev Med Virol (2003) 3.34
A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med (2011) 3.17
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology (2008) 2.99
Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. Circ Res (2002) 2.92
Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol (2005) 2.85
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J Biol Chem (2003) 2.72
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest (2012) 2.64
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Evolution, substrate specificity and subfamily classification of glycoside hydrolase family 5 (GH5). BMC Evol Biol (2012) 2.54
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2004) 2.38
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis (2007) 2.34
Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity (2013) 2.33
Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol (2003) 2.31
Local electronic properties of graphene on a BN substrate via scanning tunneling microscopy. Nano Lett (2011) 2.30
Signalling pathways in alcohol-induced liver inflammation. J Hepatol (2009) 2.29
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Serine proteases and their homologs in the Drosophila melanogaster genome: an initial analysis of sequence conservation and phylogenetic relationships. Gene (2003) 2.25
Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging (2012) 2.17
Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res (2008) 2.17
Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology (2005) 2.16
Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology (2004) 2.16
Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem (2010) 2.16
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Resting state corticolimbic connectivity abnormalities in unmedicated bipolar disorder and unipolar depression. Psychiatry Res (2009) 2.08
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
Cytokines and alcohol. Alcohol Clin Exp Res (2006) 2.04
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology (2011) 2.04
Cyclophilin A/Cluster of Differentiation 147 Interactions Participate in Early Brain Injury After Subarachnoid Hemorrhage in Rats. Crit Care Med (2015) 2.01
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Hepatitis E. N Engl J Med (2012) 1.99
Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology (2011) 1.98
Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A (2010) 1.96
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood (2002) 1.94
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A (2003) 1.93
DNA methylation in inflammatory genes among children with obstructive sleep apnea. Am J Respir Crit Care Med (2011) 1.92
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Prophenoloxidase-activating proteinase-3 (PAP-3) from Manduca sexta hemolymph: a clip-domain serine proteinase regulated by serpin-1J and serine proteinase homologs. Insect Biochem Mol Biol (2003) 1.89
GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS. J Virol (2006) 1.86
Peripheral nociception associated with surgical incision elicits remote nonischemic cardioprotection via neurogenic activation of protein kinase C signaling. Circulation (2009) 1.86
Nonproteolytic serine proteinase homologs are involved in prophenoloxidase activation in the tobacco hornworm, Manduca sexta. Insect Biochem Mol Biol (2003) 1.85
MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur J Immunol (2005) 1.85
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol (2002) 1.84
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol (2006) 1.82
Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A (2011) 1.81
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol (2008) 1.80
Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology (2012) 1.80
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem (2002) 1.80
Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol (2004) 1.79
Lymphotoxin pathway directs thymic Aire expression. Nat Immunol (2003) 1.79
Management for postoperative complications of breast augmentation by injected polyacrylamide hydrogel. Aesthetic Plast Surg (2005) 1.78
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol (2004) 1.77
PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol (2009) 1.77
Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis (2008) 1.75
Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch Neurol (2006) 1.73
Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol (2005) 1.73
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology (2007) 1.71
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol (2004) 1.71
The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol (2009) 1.70
Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Natl Acad Sci U S A (2012) 1.69
MicroRNA-127 modulates fetal lung development. Physiol Genomics (2009) 1.68